2026 年 52 巻 7 号 p. 473-484
Specialized medical institution cooperation pharmacies (SMICPs) are required to provide follow-up via telephone and other means for outpatients receiving cancer drug therapy and to share patient information with medical institutions. Nonetheless, the actual implementation status of such pharmaceutical care has not been fully elucidated. This study aimed to clarify the actual content of pharmaceutical care provided by SMICPs, with a focus on outpatients undergoing CAPOX therapy as adjuvant chemotherapy after colorectal cancer surgery. A retrospective study using medication history records was performed at three community pharmacies certified as SMICPs. The study included 56 patients scheduled to receive four courses and 43 patients scheduled to receive eight courses of CAPOX therapy. The telephone follow-up implementation rates were 62.5％ and 88.4％ in the four- and eight-course groups, respectively. No clear difference in completion rates was observed between patients with and without telephone follow-up, whereas telephone follow-up was carried out for all patients who did not complete the full courses. Among patients who completed therapy, those with more severe adverse events tended to receive a greater number of telephone follow-up calls. With respect to side effect-specific counseling, intensive guidance for hand-foot syndrome was initiated either before onset or at a mild stage. These findings suggest that telephone follow-up for patients was selectively implemented based on dose reduction, treatment interruption, or adverse events and may have functioned as a form of triage by community pharmacists. This study provides foundational data that illustrate the current state of cancer drug therapy support provided by community pharmacists in SMICPs.
